The significance of CD44 expression in gastrointestinal neuroendocrine tumors

Hepato-Gastroenterology

Volumn 52, Issue 64, 2005, Pages 1071-1076

  Lai, Chao Han ^a   Shan, Yan Shen ^a   Sy, Edgar D ^a   Hsieh, Yu Hsiang ^b   Tsai, Hung Wen ^a   Lee, Jenq Chang ^a   Lin, Pin Wen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

CD44; Gastrointestinal neuroendocrine tumor

Indexed keywords

HERMES ANTIGEN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GASTROINTESTINAL NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ADULT; AGED; ANTIGENS, CD44; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUROENDOCRINE TUMORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21744442725     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Pelley RJ, Bukowski RM: Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Onco 1997; 9:68-74.
2. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999; 340:858-868.
3. Oberg K: Carcinoid tumors: Molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002; 14:38-45.
4. Stamenkovic I, Amiot M, Pesando JM, et al: A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56:1057-1062.
5. Sherman L, Sleeman J, Herrlich P, et al: Hyaluronate receptors: Key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol 1994; 6:726-733.
6. Günthert U, Stauder R, Mayer B, et al: Are CD44 variant isoforms involved in human tumor progression? Cancer Surv 1995; 24:19-42.
7. Günthert U: CD44: A multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993; 184:47-63.
8. Lesley J, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol 1993: 54:271-335.
9. Sherman L, Sleeman J, Dall P, et al: The CD44 proteins in embryonic development and in cancer. Curr Top Microbiol Immunol 1996; 213:249-269.
10. Zhang L, Underhill CB, Chen LP: Hyaluronan on the surface of tumor cells in correlation with metastatic behavior. Cancer Res 1995; 55:428-433.
11. Yu Q, Toole BP: Common pattern of CD44 isoforms is expressed in morphogenetically active epithelia. Dev Dyn 1997; 208:1-10.
12. Bajorath J: Molecular organisation, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 2000; 39:103-111.
13. Hirata T, Fukuse T, Naiki, et al: Expression of CD44 variant exon in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998; 58:1108-1110.
14. Zolota V, Tsamandas AC, Melachrinou M, et al: Expression of CD44 protein in renal cell carcinoma: association with p53 expression. Uro Onco 2002; 7:13-17.
15. Komminoth P, Seelentag WK, Saremaslani P, et al: CD44 isoform expression in the diffuse neuroendocrine system. II. Benign and malignant tumors. Histochem Cell Biol 1996; 106:551-562.
16. Herrlich P, Morrison H, Sleeman J, et al: CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci 2000; 910:106-120.
17. Granberg D, Wilander E, Oberg K, et al: Decreased survival in patients with CD44-nagative typical bronchial carcinoid tumors. Int J Cancer 1999; 84:484-488.
18. Granberg D, Wilander E, Oberg K, et al: Prognostic makers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 2000; 85:3425-3430.
19. Perret AG, Mosnier JF, Buono JP, et al: The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol 1998; 109:286-293.
20. Solcia E, Kloppel G, Sobin LH, (In collaboration with 9 pathologists from 4 countries): Histological typing of endocrine tumors. Second Edition. WHO international histological classification of tumors. Berlin: Springer; 2000.
21. Caplin ME, Buscombe JR, Hilson AJ, et al: Carcinoid tumor. Lancet 1998; 352:799-805.
22. Bukowski RM, Johnson KG, Peterson RF, et al: A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 1987; 60:2891-2895.
23. Engstrom PF, Lavin PT, Moertel CG, et al: Streptocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984; 2:1255-1259.
24. Cheek RC, Wilson H: Carcinoid tumors. Curr Probl Surg 1970; 1:4-31.
25. Kurozumi K, Nakao K, Nishida T, et al: Significance of biological aggressiveness and proliferating activity in papillary thyroid carcinoma. World J Surg 1998; 22:1237-1242.
26. de Alava E, Panizo A, Sola I, et al: CD44v6 expression is related to progression in renal epithelial tumors. Histopathology 1998; 33:39-45.
27. Dall P, Heider KH, Sinn HP, et al: Comparison of Immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995; 60:471-477.
28. Naor D, Nedvetzki S, Golan I, et al: CD44 in cancer. Crit Rev Clin Lab Sci 2002; 39(6):527-579.
29. Sun X, Gong Y, Talamonti MS, et al: Expression of cell adhesion molecules, CD44s and E-Cadherin, and microvessel density in carcinoid tumors. Mod Pathol 2002; 15:1333-1338.
30. Liotta LA: Tumor invasion and metastasis-role of extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986; 46:1-7.
31. Gao AC, Lou W, Dong JT, et al: CD44 is a metastatic suppressor gene for prostate cancer located on human chromosome 11p13l. Cancer Res 1997; 57:846-849.
32. Lou W, Krill D, Dhir R, et al: Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 1999; 59:2329-2331.
33. Giovannini M, Robanus-Maandag E, Niwa-Kawakita M, et al: Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 1999; 13:978-986.
34. Coppola D, Clarke M, Landreneau R, et al: Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung. Mod Pathol 1996; 9:484-490.
35. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133:1710-1715.
36. Pelosi G, Bresaola E, Bogina G, et al: Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27:1124-1134.
37. Kloppel G, Perren A, Heitz PU: From carcinoids to a biologically and prognostically relevant classification of the neuroendocrine tumors of gastrointestinal tract and the pancreas. Acta Clin Croat 2002; 41:285-294.